Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Krka DDFRA:KN8 -2.83%68 9-Day RSI is 44.39 as of Jul. 26, 2026. GuruFocus rates FRA:KN8 with a GF Score™ of 68/100 and a GF Value™ of €194.14 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 1,045 Drug Manufacturers companies, Krka DD ranks better than 52.44% on this metric.
The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
As of today (2026-07-26), Krka DD's 9-Day RSI is 44.39.
The industry rank for Krka DD's 9-Day RSI or its related term are showing as below:
FRA:KN8's 9-Day RSI is ranked better than 52.44% of 1045
companies
in the Drug Manufacturers industry
Industry Median: 46.28
vs FRA:KN8: 44.39
Krka DD (FRA:KN8) 9-Day RSI Explanation
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
Krka DD 9-Day RSI Related Terms
FRA:KN8 vs ZTS, UTHR, VTRS: 9-Day RSI Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Krka DD's 9-Day RSI, along with its competitors' market caps and 9-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Krka DD 9-Day RSI vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Krka DD's 9-Day RSI distribution charts can be found below:
* The bar in red indicates where Krka DD's 9-Day RSI falls into.
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Krka DD (FRA:KN8) has a 9-Day RSI of 44.39 as of Jul. 26, 2026. According to the industry distribution chart, Krka DD ranks #497 out of 1045 companies in the Drug Manufacturers industry, placing it in the top 47.6%.
Is Krka DD's 9-Day RSI too high?
Krka DD's current 9-Day RSI is 44.39. The Drug Manufacturers industry median 9-Day RSI is 46.28. Krka DD's value of 44.39 is 4.1% below this industry median. Based on the distribution chart, Krka DD ranks #497 out of 1045 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Krka DD has a GF Score™ of 68/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Krka DD's 9-Day RSI compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Krka DD ranks #497 out of 1045 companies for 9-Day RSI. This puts Krka DD in the upper half of its industry. The industry median 9-Day RSI is 46.28. Krka DD's value of 44.39 is 4.1% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 9-Day RSI for a Drug Manufacturers company?
The median 9-Day RSI among Drug Manufacturers companies is 46.28, based on 1,045 companies in the industry. Companies in the top quartile (top 25%) have a 9-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 9-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Krka DD's current 9-Day RSI of 44.39 is 4.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 9-Day RSI mean?
A high 9-Day RSI can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median 9-Day RSI is 46.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Krka DD's current 9-Day RSI is 44.39. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Krka DD stock overvalued right now?
Based on GuruFocus' analysis, Krka DD (FRA:KN8) is currently considered Significantly Overvalued. The stock's GF Value™ is €194.14, compared to a current price of €257.50 — trading 32.6% above its estimated fair value. The current 9-Day RSI is 44.39 and 4.1% below the Drug Manufacturers industry median of 46.28. Krka DD's overall GF Score™ is 68/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 9-Day RSI calculated?
9-Day RSI is calculated from a company's financial statements. For Krka DD (FRA:KN8), the current 9-Day RSI is 44.39 as of Jul. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Krka DD (FRA:KN8) Overvalued in 2026?
Based on GuruFocus' analysis, Krka DD stock appears to be overvalued.
The current stock price of €257.50 is trading 32.6% above its estimated GF Value™ of €194.14.
GuruFocus considers Krka DD to be Significantly Overvalued.
Key valuation signals for FRA:KN8:
9-Day RSI: 44.39
GF Value™: €194.14 vs. price of €257.50 (32.6% above fair value)
Industry Position: 4.1% below the Drug Manufacturers median (#497 of 1045)
No single metric tells the full story. See the FRA:KN8 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Krka DD engages in the development, production, marketing, and sales of human health products (prescription pharmaceuticals and non-prescription products), animal health products, health resorts, and tourist services. The company's products in Prescription pharmaceuticals include Cardiovascular diseases, Infections, and Oncology; Non-prescription products include Cold and cough products, nasal products, vitamins and minerals, and hair care products; and Animal health products include Antimicrobials and disinfectants, among others. It operates across the European Union, South-East Europe, Eastern Europe region, and Others. The company derives a majority of its revenue from the European Union.
68GF Score
Get the complete analysis for FRA:KN8
9-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:KN8 has been successfully added to your 
